Novartis' Phase 3 pelacarsen study miss raises the stakes for Amgen, Lilly
Phase 3negativepelacarsenNegative
AI Analysis
Summary
Novartis' Phase 3 pelacarsen study failed to meet primary endpoint, showing no superiority over placebo in a cardiovascular outcomes trial. This marks the third major cardiovascular trial failure among top pharma companies in two months, following similar setbacks from Novo Nordisk and AstraZeneca.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
pelacarsen was no better than placebo in cardiovascular outcomes trial
Importance:8/10
Sentiment:
-0.90
cardiovasculartrial failurePhase 3pelacarsen
Related Companies
Read the original article
Published by Endpoints News on September 7, 2026 2:48 PM